At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Advisory Committee on Immunization Practices convened to make expanded vaccine recommendations amidst CDC leadership changes.

This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.

China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...